Samer Jallad is a senior student at the Faculty of Pharmacy, Beirut Arab University (BAU). He joined the junior research team at the faculty where outstanding students with interest in research apply their knowledge in phytotherapy research..Samer attended several conferences in Lebanon and Berlin where he presented posters in collaboration with his colleagues of the junior research team..He had 2 internships at Astrazeneca® Pharmaceuticals in summer 2015 and 2016.He is also a member of the student activities committee and a member of the Quality Assurance Unit, Faculty of Pharmacy at BAU.
Mohammad Houri is a senior outstanding Undergraduate Pharmacy student at Beirut Arab University graduating in July 2017. He is willing to continue his Postgraduate studies in Pharmaceutical Sciences. Mr. Houri is a leader of a group in Junior Research team; moreover, he presented posters in several conferences about Diabetes disease and attended several conferences and recently is waiting for the approval for a review article done about Neuropathic Pain Management in Diabetes disease. Mr. Houri is a member in Quality Assurance Unit at Faculty of pharmacy at BAU and is the faculty representative since 2014. His current interest is in Diabetes care management and in improving healthcare and preventive measures worldwide.
Upon injury of the nerves, centrally or peripherally, neuropathic pain (NP) occurs. NP is a type of chronic pain a significant number of patients suffer from. Diagnosis of NP is usually presented as tingling, shooting, or burning sensation. Patients describe this pain agonizing and affecting their quality of life. Although poorly understood this syndrome accompanies a broad range of chronic malignancies. Therefore, it is essential to search for more evidence for precise diagnosis and optimum treatment. The purpose of this work is to summarize the results related to NP in terms of types, etiology, diagnosis, and current and future treatment prospective. Due to insufficient evidence, the current treatment is still under expectation. Phytotherapies provide low-risk options in NP patients and might be the future of NP management. Recently, neuropathic patients are increasingly relying on phytotherapy as a bright source of healthcare. Moreover, research on combination therapies involving pharmacotherapy with phytotherapy looks very promising. The aim of the combination therapy is to minimize toxicities while optimizing therapeutic effects for neuropathic patients to have better quality of life. Hence, health-care professionals should be routinely updated with NP phytotherapy, keeping in mind the risk to benefit profile of using natural plants in the treatment of neuropathic pain.
Dr. Aka has completed her Pharm.D. at the age of 26 years from Howard University College of Pharmacy in Washington, DC, and is completing her postdoctoral studies as a Health Outcomes Research Fellow at Howard University. She has published abstracts, oral, and poster presentations at various conferences in disease management and innovative delivery of care sevices. Jennifer has traveled to Pretoria, South Africa to deliver research in infectious disease and has an interest in enhancing care for the underserved and minority population. Her current interest is in diabetes care management and to improve both national and international healthcare.
The American Diabetes Association recognizes that elevated hemoglobin A1c directly correlates with increased diabetes-related complications and mortality. Pharmacist-led medication therapy management has proven effectiveness in controlling hemoglobin A1c, and achieving both positive clinical and economic outcomes. However, there is a scarcity of research on medication therapy management in the Medicaid population. Studies have demonstrated that the Medicaid population has the highest risk of developing diabetes-related complications and disease-related death. The objective of this study is to determine the clinical and economic outcomes of implementing a pharmacist-led medication therapy management diabetes program to enhance care for high-risk Medicaid beneficiaries. Methods Participants that will be included in this quasi-experimental study are members of a DC Medicaid Health Plan. The Medicaid health plan members will be followed for a period of 12 months at the health plan's wellness center. The participants will be managed in a collaborative fashion by an interdisciplinary health care team. The pharmacist will integrate appointment-based medication therapy management services (this includes comprehensive medication review, medication counseling, and blood glucose meter teaching) to each participant. The inclusion criteria will include at the point of recruitment: ages 18-75; or diagnosis of type 1 or 2 diabetes with hemoglobin A1c >9; or utilizers of 4 or more prescriptions; or have had a recent 30-day readmission to the hospital. The data collected will be electronic medical records, and both prescription and hospital visit claims data. Descriptive statistics will be used to describe the population. The statistical analysis used will be the difference-in- differences approach with a multivariate regression analysis to evaluate the impact of the pharmacist intervention on the primary outcomes, after adjusting for other covariates. The primary outcomes will be the effect on 1) hemoglobin A1c, 2) hospital readmission rate, and 3) total health care utilization.